CMS Heart Failure Pulmonary 
Becker's Hospital Review - Cardiology
JANUARY 13, 2025
"CMS proposes Medicare and Medicaid coverage for implantable pulmonary artery pressure sensors to manage heart failure. Final decision to be published on Jan.
Becker's Hospital Review - Cardiology
OCTOBER 31, 2024
"CMS has proposed coverage of implantable pulmonary artery pressure sensors for heart failure management. Learn about the criteria and public comment period."
DAIC
MAY 2, 2024
a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. Getty Images milla1cf Thu, 05/02/2024 - 10:12 May 2, 2024 — BioCardia, Inc. ,
DAIC
MARCH 13, 2024
CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,
DAIC
JULY 25, 2024
FDA granted CardiAMP Cell Therapy a Breakthrough Device Designation for the treatment of ischemic heart failure. Leslie Miller, MD , trial investigator at the CHF Heart Function Clinic at BayCare Morton Plant Hospital in Clearwater, Florida and a member of the CardiAMP Heart Failure II Study Executive Steering Committee. “As
DAIC
JULY 29, 2024
Edwards anticipates FDA approval of the JenaValve Trilogy Heart Valve System in late 2025, which will represent the first approved therapy for patients suffering from AR. Building on an investment made in 2016, Edwards has exercised its option to acquire Endotronix , a leader in heart failure (HF) management solutions.
Expert insights. Personalized for you.
52 
Let's personalize your content